NanoCarrier Co., Ltd. (4571) AI Stock Analysis

• Market Cap: ¥9.39B
• Dividend Yield: N/A
• Average Volume (3M): 763.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: -30.46%
• EPS Growth: 39.41%
• Country: JP
• Employees: 18
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -3.40
• Shares Outstanding: 70,625,460
• 10 Day Avg. Volume: 1,077,350
• 30 Day Avg. Volume: 763,530
• PEG Ratio: -0.79
• Price to Book (P/B): 3.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: ―

NanoCarrier Co., Ltd. faces significant financial challenges, with declining revenues and negative cash flows. While the company's balance sheet shows a strong equity position, operational and profitability issues are concerning. Technical analysis indicates a bearish trend, and the negative P/E ratio reflects ongoing financial struggles. These factors result in a low overall stock score, reflecting the company's current difficulties and uncertain outlook.

NanoCarrier Co., Ltd. Business Overview & Revenue Model

Company Description

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.

How the Company Makes Money

NanoCarrier Co., Ltd. generates revenue primarily through the development, licensing, and commercialization of its proprietary drug delivery systems. The company collaborates with pharmaceutical companies to co-develop drugs using its nanotechnology platforms, earning revenues from licensing fees, milestone payments, and royalties on sales of co-developed products. Additionally, NanoCarrier may receive funding from government grants or private investments to support its research and development activities. Strategic partnerships and collaborations with other biotech and pharmaceutical companies also play a significant role in enhancing its market reach and financial performance.

NanoCarrier Co., Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	114.20M	135.51M	202.19M	264.03M	313.26M	552.97M
Gross Profit	78.97M	110.96M	159.60M	222.74M	274.89M	475.01M
EBITDA	-661.00M	-863.00M	-1.30B	-2.06B	-1.30B	-1.10B
Net Income	-637.63M	-780.00M	-1.31B	-1.88B	-2.84B	-2.01B
Balance Sheet
Total Assets	4.18B	5.07B	5.78B	7.14B	7.82B	8.94B
Cash, Cash Equivalents and Short-Term Investments	3.52B	4.28B	4.44B	5.95B	6.40B	7.47B
Total Debt	540.00M	1.11B	1.11B	1.15B	0.00	0.00
Total Liabilities	1.20B	1.65B	1.53B	1.57B	321.00M	175.60M
Stockholders Equity	2.98B	3.42B	4.25B	5.57B	7.50B	8.77B
Cash Flow
Free Cash Flow	0.00	-585.08M	-1.09B	-1.76B	-1.25B	-1.14B
Operating Cash Flow	0.00	-585.08M	-1.09B	-1.75B	-1.25B	-1.14B
Investing Cash Flow	0.00	793.01M	1.21B	-244.13M	-871.69M	-112.34M
Financing Cash Flow	0.00	3.73M	32.20M	1.15B	-11.46M	2.16B

NanoCarrier Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 141.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Negative. The current price of 141 is above the 20-day moving average (MA) of 137.90, above the 50-day MA of 133.42, and below the 200-day MA of 150.94, indicating a bearish trend. The MACD of 1.26 indicates Positive momentum. The RSI at 44.92 is Neutral, neither overbought nor oversold. The STOCH value of 5.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4571.

NanoCarrier Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4507	80 Outperform	$2.24T	12.73	12.99%	2.27%	0.73%	7.75%
4577	73 Outperform	¥29.85B	14.04		3.53%	8.07%	-45.20%
4568	67 Neutral	$6.15T	21.15	17.60%	1.82%	17.77%	49.34%
4579	54 Neutral	¥13.13B	―		―	57.13%	-66.39%
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%
4582	51 Neutral	¥8.09B	―		―	-56.12%	-73.82%
4571	40 Underperform	¥9.39B	―	-26.97%	―	-30.46%	39.41%